Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
Holding VXRT?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: 11.27%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the company's COVID-19 oral vaccine program with strong funding and partnership with BARDA, along with notable revenue growth. However, challenges remain in the norovirus program with the need for additional data as requested by the FDA. Overall, the positive developments in the COVID-19 and HPV programs, alongside revenue growth, present an optimistic outlook.Company Guidance
During the Vaxart Q3 2024 earnings call, the company provided guidance on several key metrics related to its clinical programs and financial standing. Vaxart highlighted the progress of its COVID-19 oral pill vaccine program, which is in a Phase IIb study involving 400 participants initially, with plans to expand to 10,000. This trial, supported by a BARDA project valued up to $456 million, aims to demonstrate the efficacy of the oral vaccine compared to a traditional mRNA vaccine. Additionally, Vaxart reported substantial interest in enrollment and outlined a strategic path forward for its norovirus program following feedback from the FDA. Financially, Vaxart achieved $4.9 million in revenue for Q3 2024, up from $2.1 million in the same quarter the previous year, primarily driven by government contracts. The company concluded the quarter with $58.7 million in cash and anticipates a cash runway extending into 2026.BARDA Partnership and COVID-19 Oral Vaccine Progress
Vaxart has started enrollment in a Phase IIb study for their COVID-19 oral pill vaccine candidate, funded by BARDA with a project valued up to $456 million. The study aims to evaluate their vaccine against an approved mRNA vaccine comparator, showing strong interest and enrollment progress.
Revenue Growth
Revenue for the third quarter of 2024 was $4.9 million, compared to $2.1 million in the third quarter of 2023, primarily from government contracts related to BARDA.
Norovirus Program Feedback
Constructive feedback received from FDA for norovirus program, with promising data presented at Infectious Disease Week and World Vaccine Congress. The program has shown robust immunogenicity and benign safety profile.
HPV Vaccine Progress
Published promising preclinical data on HPV vaccine constructs, showing potential noninvasive approach to prevent cervical cancer, with additional studies planned.
---
VXRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VXRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.71 | $0.63 | -11.27% |
| Aug 08, 2024 | $0.63 | $0.58 | -7.94% |
| May 13, 2024 | $0.82 | $0.86 | +4.88% |
| Mar 14, 2024 | $1.10 | $1.08 | -1.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vaxart Inc (VXRT) report earnings?
Vaxart Inc (VXRT) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Vaxart Inc (VXRT) earnings time?
Vaxart Inc (VXRT) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VXRT EPS forecast?
VXRT EPS forecast for the fiscal quarter 2024 (Q4) is -0.1.
---